SYS Labs ’ EVM-L2 scaling platform Rollux set for launch end of June
The mainnet release date for Rollux, SYS Labs’ ground-breaking EVM-L2 scaling platform, was announced on June 1 and is expected to revolutionize the blockchain industry by establishing brand-new benchmarks in terms of transaction speed, security, and cost. Rollux is scheduled to launch on June 28,…#syslabs #finbold #optimistic #jagdeepsidhu #superdapp #pegasys #nft #paliwallet #daosys #dao (Source: Reuters: Health)
Source: Reuters: Health - June 2, 2023 Category: Consumer Health News Source Type: news
Pegasys (peginterferon alfa-2a)
Title: Pegasys (peginterferon alfa-2a)Category: MedicationsCreated: 10/22/2020 12:00:00 AMLast Editorial Review: 10/22/2020 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - October 22, 2020 Category: Drugs & Pharmacology Source Type: news
Pegasys (Peginterferon alfa-2a) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 3, 2017 Category: Drugs & Pharmacology Source Type: news
EU expands use of Roche's Pegasys in chronic hepatitis C
ZURICH (Reuters) - Roche said on Monday the European Medicines Agency (EMA) has expanded the approval of its drug Pegasys plus ribavirin for the treatment of chronic hepatitis C virus (HCV) to children five years of age and older. (Source: Reuters: Health)
Source: Reuters: Health - March 18, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Roche's Pegasys receives EU approval for the treatment of chronic hepatitis C in children five years of age and older
Roche announced today that the European Medicines Agency (EMA) has expanded the approval of Pegasys (peginterferon alfa-2a) plus ribavirin for the treatment of chronic hepatitis C virus (HCV). The new label includes children and adolescents five years of age and older, who have not received treatment and who have tested positive for the virus. (Source: Roche Media News)
Source: Roche Media News - March 18, 2013 Category: Pharmaceuticals Source Type: news
Roche's Pegasys receives EU approval for the treatment of chronic hepatitis C in children five years of age and older
Roche announced today that the European Medicines Agency (EMA) has expanded the approval of Pegasys (peginterferon alfa-2a) plus ribavirin for the treatment of chronic hepatitis C virus (HCV). The new label includes children and adolescents five years of age and older, who have not received treatment and who have tested positive for the virus. Pegasys in combination with the antiviral ribavirin is the foundation of treatment for chronic HCV in adults. The medicine was first approved in the European Union over ten years ago. (Source: Roche Investor Update)
Source: Roche Investor Update - March 18, 2013 Category: Pharmaceuticals Source Type: news
CHMP recommends extension of peginterferon alfa-2a (Pegasys®) license to include use in hepatitis C treatment from 5 years of age
Source: European Medicines Agency
Area: News
The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a new indication for peginterferon alfa-2a (Pegasys®), as follows:
"Pegasys in combination with ribavirin is indicated for the treatment of chronic hepatitis C in treatment-naïve children and adolescents 5 years of age and older, who are positive for serum HCV-RNA. When deciding to initiate treatment in childhood, it is important to consider growth inhibition induced by combination therapy. The reversibility of growth inhibition is uncertain. The decision to treat should be m...
Source: NeLM - News - January 21, 2013 Category: Drugs & Pharmacology Source Type: news
